{"id":"W2133389067","doi":"10.1200/jco.2007.14.2372","title":"Phase I-II Trial of Bortezomib Plus Oral Cyclophosphamide and Prednisone in Relapsed and Refractory Multiple Myeloma","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Bortezomib; Prednisone; Regimen; Cyclophosphamide; Refractory (planetary science); Internal medicine; Multiple myeloma; Gastroenterology; Surgery; Urology; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.002159359,0.0001515558,0.001791515,0.0002073151,0.00006119892,0.000003060311,0.00008974368,0.0003798903,0.00003960343],"category_scores_gemma":[0.008755589,0.0001075336,0.0002233087,0.0001340818,0.0005337418,0.0001065993,0.00008956161,0.0008893945,0.000001916042],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001364233,"about_ca_system_score_gemma":0.001544641,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001093575,"about_ca_topic_score_gemma":0.0001025484,"domain_scores_codex":[0.9963727,0.0004536293,0.002252172,0.0002242854,0.000416071,0.0002811129],"domain_scores_gemma":[0.9953342,0.002556105,0.001102184,0.0001800396,0.0002380315,0.0005894534],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5272167,0.01640764,0.2158985,0.00004789851,0.0004614956,0.005963204,0.0003683095,0.000002376639,0.0008127522,0.000008803468,0.0008450901,0.2319672],"study_design_scores_gemma":[0.4987668,0.09237756,0.4007994,0.00008444028,0.0001210411,0.0006351753,0.00006147782,0.0003969882,0.0001605282,0.00005365581,0.006469878,0.00007311055],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9963984,0.001168649,0.00001132973,0.001086413,0.0003677689,0.0005141842,0.00000867876,0.000005662475,0.0004389101],"genre_scores_gemma":[0.9916919,0.004195606,0.003298126,0.0001736885,0.000350809,0.000006919362,0.000004139568,0.00001499704,0.000263847],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2318941,"threshold_uncertainty_score":0.9995941,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1545208364887073,"score_gpt":0.4762083366351059,"score_spread":0.3216875001463986,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}